[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.166.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
December 28, 2011

Missing the Mark on Prostate-Specific Antigen Screening

Author Affiliations

Author Affiliations: Department of Urology and Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor.

JAMA. 2011;306(24):2719-2720. doi:10.1001/jama.2011.1879

The US Preventive Services Task Force recently issued a draft recommendation against prostate-specific antigen (PSA) screening for prostate cancer.1 After performing a rigorous review of the relevant empirical literature, the task force concluded with “moderate certainty” that the harms of PSA-based detection (eg, biopsy-related complications) and early intervention (eg, incontinence, erectile dysfunction) exceed the potential benefits. For this reason, the task force now proposes discouraging PSA screening among men who are free of symptoms suspicious for prostate cancer.

First Page Preview View Large
First page PDF preview
First page PDF preview
×